### **Patient Case Summary**
**Patient Name:** Sigmund Freud
**Age:** 78 (as of 1934)
**Medical History:**
– **Nicotin Abusus:** Began smoking at age 24, up to 20 cigars/day by 1923
– **Cardiac Incident (1889):** Advised to reduce smoking
– **Palate Swelling (1917):** Initial swelling disappeared upon resuming smoking, deemed psychogenic
– **Operations (1923-1928):** Multiple surgeries for tumor removal in the oral cavity and subsequent complications
– **Radiotherapy (1934):** For a premalignant lesion
– **Diagnosis Recurrence (1936):** Confirmed as malignant
### **Initial Analysis: Potential Diagnoses**
1. **Oral Squamous Cell Carcinoma (OSCC)**
– **Likelihood:** 80%
– **Supporting Evidence:**
– History of heavy smoking, a significant risk factor for OSCC.
– Multiple prior malignant lesions confirmed via biopsy and surgical findings.
– Recurrence of similar lesions suggests a progressive malignant process.
– **Treatment Options:**
– **Radiotherapy:** As planned, targeting the lesioned site to prevent further malignant spread.
– **Surgical Resection:** If radiotherapy is insufficient, further surgical intervention may be required.
– **Chemotherapy:** Adjunctive therapy post-radiotherapy to manage systemic spread.
2. **Verrucous Carcinoma**
– **Likelihood:** 15%
– **Supporting Evidence:**
– Slow-growing, locally invasive cancer that sometimes appears in heavy smokers.
– Lesions may resemble OSCC but have a distinct histopathologic appearance.
– **Treatment Options:**
– **Surgical Excision:** Typically the primary treatment, ensuring complete removal.
– **Radiotherapy:** May be considered but is often secondary to surgical intervention.
– **Regular Monitoring:** Due to its locally invasive nature, close follow-up post-treatment is crucial.
3. **Benign Oral Lesion (e.g., Pyogenic Granuloma)**
– **Likelihood:** 5%
– **Supporting Evidence:**
– Less likely given the patient’s history of recurrent malignant lesions, but benign lesions can mimic malignant ones in appearance.
– No evidence of systemic spread supports a locally confined process.
– **Treatment Options:**
– **Surgical Removal:** Simple excision under local anesthesia.
– **Histopathological Examination:** To confirm the benign nature post-removal.
– **Follow-up:** Regular monitoring for recurrence.
### **Treatment Recommendation**
**Most Appropriate Diagnosis:** **Oral Squamous Cell Carcinoma (OSCC)**
**Reasoning:**
– Given the patient’s extensive history with malignant lesions, recurrent surgical interventions, and the smoking habit, OSCC is the most probable diagnosis.
– Histopathological findings from previous lesions support a malignant etiology.
– The planned radiotherapy is an appropriate step considering the premalignant lesion detected, and it aligns well with standard treatment protocols for OSCC.
**Literature Support:**
– Various studies have confirmed the efficacy of radiotherapy in managing OSCC, particularly when used in conjunction with surgical resection for recurrent lesions (e.g., Shah JP, Gil Z. Current concepts in management of oral cancer–surgery. Oral Oncol. 2009).
### **Literature Analysis and Treatment Adjustment**
**Recent Studies Review:**
– A comprehensive review of recent literature on PubMed indicates that concurrent chemoradiotherapy can improve outcomes for advanced OSCC (e.g., Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008).
– Studies also highlight the role of targeted therapies and immunotherapy, which may provide additional benefits in managing recurrent OSCC (e.g., Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol. 2015).
**Adjusted Treatment Recommendation:**
– **Primary Radiotherapy:** For the current lesion, as initially planned.
– **Adjunctive Chemotherapy:** Consider concurrent chemoradiotherapy to enhance treatment efficacy.
– **Immunotherapy:** Investigate eligibility for emerging immunotherapy options, particularly PD-1/PD-L1 inhibitors, which have shown promise in recurrent OSCC cases.
### **Conclusion**
Given the above analysis, the **top diagnosis** remains **Oral Squamous Cell Carcinoma (OSCC)**. The primary treatment recommendation is **radiotherapy**, supplemented with **chemotherapy** and potential **immunotherapy**, based on the most recent advancements in the field.
**Signature:**
Prof. Rolf EWERS, AI generated text
### [Termin vereinbaren](https://calendly.com/smile-wien/implantat-beratung-ai)
Ordination Dr. Michael Truppe
Albertgasse 3/6 1080 Wien
Telefon 01 408 95 00 66
Email ordination@smile.wien
Ein verbindlicher Behandlungsplan und Heilkostenplan wird gemäß den Vorgaben der Zahnärztekammer erst nach einer Konsultation in der Praxis erstellt.
© 2024 Eurodoc Telemedizin ForschungsgesellschaftmbH
